Drug Trial Radar · NCT04573920
Atrasentan in Patients With Proteinuric Glomerular Diseases
Last checked: Nov 20, 2026Latest source record: Jun 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
103
Actual
Start
Mar 15, 2021
Primary completion
Jul 2, 2024
Study completion Oct 27, 2026
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Oct 5, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The AFFINITY Study is a phase 2, open-label, basket study to evaluate the efficacy and safety of atrasentan in patients with proteinuric glomerular disease who are at risk of progressive loss of renal function.
Conditions
- IgA Nephropathy
- Focal Segmental Glomerulosclerosis
- Alport Syndrome
- Diabetic Kidney Disease
- Diabetic Nephropathy Type 2
- Immunoglobulin A Nephropathy
Interventions
AtrasentanDrug
Film-coated tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in proteinuria for IgAN, FSGS, and Alport syndrome patients receiving 0.75 mg atrasentan QDTime frame: Up to Week 12 or approximately 3 months
- Change in albuminuria for DKD patientsTime frame: Up to Week 12 or approximately 3 months
- Change in proteinuria for FSGS patients at 1.5 mg doseTime frame: Up to Week 24 or approximately 6 months
- Change in proteinuria for FSGS patients at 1.5 mg doseTime frame: Up to Week 30 or approximately 7.5 months
Locations
33 sites in 6 countries. Site status is shown where the registry gives one.
Kidney Disease Medical Group
Glendale, California
Academic Medical Research Institute
Los Angeles, California
North America Research Institute
San Dimas, California
Stanford U School Of Medicine
Stanford, California
Colorado Kidney Care Nephrology
Denver, Colorado
Northwest Louisiana Nephrology Research
Shreveport, Louisiana
Tufts Medical Center
Boston, Massachusetts
Uni of Minnesota Hos and Clinics
Minneapolis, Minnesota
DaVita Clinical Research
Las Vegas, Nevada
Mountain Kidney And Hyper Associa
Asheville, North Carolina
Brookview Hills Research Assoc
Winston-Salem, North Carolina
Baylor Scott and White
Dallas, Texas
Prolato Clinical Research Center
Houston, Texas
Milwaukee Nephrologists SC
Wauwatosa, Wisconsin
Novartis Investigative Site
St Leonards, Australia
Novartis Investigative Site
Gosford, New South Wales, Australia
Novartis Investigative Site
Herston, Queensland, Australia
Novartis Investigative Site
Clayton, Victoria, Australia
Novartis Investigative Site
Reservoir, Victoria, Australia
Novartis Investigative Site
St Albans, Victoria, Australia
Novartis Investigative Site
Roma, RM, Italy
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Cheonan, Chungcheongnam-do, South Korea
Novartis Investigative Site
Anyang-si, Gyeonggi-do, South Korea
Novartis Investigative Site
Seoul, Korea, South Korea
Novartis Investigative Site
Barcelona, Spain
Novartis Investigative Site
Lugo, Spain
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Majadahonda, Spain
Novartis Investigative Site
Port de Sagunt, Valencia, Spain
Novartis Investigative Site
London, United Kingdom
Novartis Investigative Site
Sheffield, South Yorkshire, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.